Measuring the impact of improved diagnostics on antimicrobial stewardship in respiratory tract infection (MIDAS Study)

HS Lothian0 个研究点目标入组 600 人开始时间: 2019年7月18日最近更新: 2019年8月26日

试验速览

暂无简介。

•1. Aged 18 and over
•2. Hospitalised
•3. Lower respiratory tract specimen taken for routine microbiology within 48 hours of admission and - 3 or more of following signs or symptoms of respiratory tract infection:
•-new or worsening cough
•-new or worsening expectoration of sputum
•-haemoptysis
•-new or worsening dyspnea
•-pleuritic chest pain
•-abnormalities on chest auscultation or percussion

•1. Hospitalisation for more than 48 hours
•2. No capacity to consent
•3. Active malignancy
•4. Immunodeficiency - defined as being on long term (?28 days) oral prednisolone 10mg or more per day or other long term disease modifying drug
•5. Solid organ transplant
•6. All forms of pulmonary fibrosis including usual interstitial pneumonia, asbestosis, non-specific interstitial pneumonia, hypersensitivity pneumonitis, active sarcoidosis
•7. Palliative treatment only
•8. Mechanical ventilation
•9. End of life care
•10. Previously randomised into this trial
•11. Participation in another CTIMP or CIMD interventional study

发起方

HS Lothian